---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-347524"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2026-08-13T01:36:55+00:00"
generated_at: "2026-08-13T10:10:34.042508+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Sangamo selects PTC and Lilly as winning bidders in $163.55M asset auction

## Summary
- PTC to buy Fabry program (ST-920) for $111M cash + up to $100M milestones ($80M on accelerated approval, $20M on full approval).
- Lilly to buy capsid delivery, zinc finger, MINT platforms and prion program (ST-506) for $50M cash.
- Tools/equipment sold to various bidders for $2.55M; total cash consideration ~$163.55M.
- Sales subject to Bankruptcy Court approval; Lilly close expected ~Sept 4, 2026; PTC close after HSR review.
- Company continues to market ST-503, hemophilia A program, cell therapy and T-Reg assets.

## SEC filing metadata
- accession: 0001193125-26-347524
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2026-08-13T01:36:55+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000119312526347524/0001193125-26-347524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000119312526347524/d125617d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-347524
- JSON: https://secwatch.observer/filing/0001193125-26-347524.json
- Plain text: https://secwatch.observer/filing/0001193125-26-347524.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.